Company intelligence / Profile preview

Altea Therapeutics

Atlanta/Tucker, Georgia, USAventureradar.com ↗

Ownership: Private
Development stage: Other

Overview

Altea Therapeutics developed a proprietary transdermal drug delivery platform called PassPort™, designed to deliver proteins, peptides, small molecules, genes, and vaccines through the skin using a needle-free patch. The system was evaluated in early-stage clinical trials for basal insulin in type 1 diabetes and hydromorphone for acute/chronic pain. The company was acquired by Nitto Denko Corporation in April 2012; its technology is now part of Nitto's portfolio.

Therapeutic areas: EndocrinologyNeurology
Modalities: Small moleculeProteinPeptidesGene therapy (via transdermal delivery)Vaccine (via transdermal delivery)
Industry: Biotech

Beyond the preview

Go deeper on Altea Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Altea Therapeutics.

Explore the full profile